Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have lymphoma and also show signs of a serious immune overreaction called HLH (haemophagocytic lymphohistiocytosis), meeting at least one of the following two sets of conditions:
- People whose condition meets 5 out of 8 specific medical signs listed in the HLH-2004 diagnostic guidelines (confirm with trial site for the full list of signs)
- People whose blood test results show a specific protein level (sCD25) above 3,900 U/mL and a ferritin level above 1,000 ng/mL, which together indicate a positive result on a scoring system called the OHI index
Who may not be able to join:
- People with an aggressive form of lymphoma whose HLH symptoms developed more than one month after their lymphoma was first diagnosed
- People whose medical records do not fully document their treatment history and how their condition responded to treatment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Gaurav Goyal, MD, University of Alabama at Birmingham
Phone: 205-934-1816
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To determine the factors predicting 180 days overall survival of patients with cancer that are HLH-2004/OHI+
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.